gsk glp 1 agonist How GLP-1 Receptor Agonists Evolved from Diabetes to Weight Loss Treatments List of GLP-1 Receptor Agonists

One crucial observation made in the early clinical trials with GLP-1RA was that treated patients consistently lost weight relative to controls receiving placebo

These combined mechanisms underpin their efficacy for both weight reduction and cardiometabolic protection ( In recent years, the remarkable efficacy of tirzepatide, a dual GIP/GLP-1 receptor agonist, has emerged ( However, these benefits are accompanied by concerns about side effects, cost, long-term sustainability and, above all, the loss of lean mass, which may be mitigated by concurrent exercise ( Exercise and lifestyle interventions remain foundational for obesity and metabolic disease management, offering broad health benefits, but are often limited by adherence and modest long-term weight loss ( Recent randomized controlled trials and meta-analyses suggest that combining GLP-1RAs with exercise may yield additive or synergistic effects on weight loss and metabolic syndrome severity as well as on oxidative stress and inflammation

Observational data suggest that muscle wasting is not disproportionately accelerated by GLP-1RAs compared to other weight-loss interventions

Gastroparesis: etiology, clinical manifestations, and diagnosis

Further, some PCPs worry about lack of reimbursement for time spent discussing obesity, but obesity codes are often now reimbursed

Patients should be asked about the use of other medications and medical conditions, which may exacerbate gastrointestinal symptoms and delay gastric emptying, such as, but not limited to bowel dysmotility, gastroparesis, and Parkinsons disease